Autochthonous Hepatitis E Virus Infections: A New Transfusion-Associated Risk?

Jens Dreier a  David Juhl b

a Institute for Laboratory and Transfusion Medicine, Heart and Diabetes Center NRW, Ruhr-University Bochum, Bad Oeynhausen, Germany
b Institute of Transfusion Medicine, University Hospital of Schleswig-Holstein, Lübeck, Germany

Introduction

Hepatitis E virus (HEV) is a non-enveloped single-stranded RNA virus approximately 27–34 nm in diameter belonging to the genus Hepevirus in the Hepeviridae family. This family contains mammalian HEV and the more distant avian HEV [1], as well as cut-throat trout virus [2]. The 2 latter groups represent a potential separate genus without association to human beings. Phylogenetic analysis of various mammalian HEV isolates circulating among human beings and animals has led to the recognition of 4 major genotypes (genotypes 1–4) and several subgenotypes [3–5]. All HEV genotypes represent a single serotype. Genotypes 1 and 2 are circulating in Africa and Asia, genotype 3 shows a broad distribution worldwide, and genotype 4 is restricted to Asia [6]. Genotypes 3 and 4 are generally less pathogenic, and are enzootic in a variety of wild and domestic animals, in particular wild boar and pigs [4, 7, 8]. Lately, HEV has been detected in bats and rodents [9–11], indicating that these mammals may be a reservoir for HEV and an additional source for transmission to humans. The classification of HEV variants is currently in transition without agreed definitions for genotypes and subtypes or for deeper taxonomic groupings into species and genera. Smith and coworkers [9] recommend a genetic classification of HEV into 4 species as follows: group A, HEV isolates that infect humans or are closely related to such isolates (genotypes 1–4, the 2 wild boar isolates, and the rabbit isolates); group B, avian HEV; group C, bat HEV; and group D, rat HEV and ferret HEV. The more divergent HEV-like virus from fish (cut-throat trout virus) would represent a plausible candidate member of a second genus within the Hepeviridae.

Zoonotic transmission of HEV occurs either by consumption of contaminated meat and meat products, or by contact with infected animals [12]. The virus is ubiquitous in the do-
HEV infection can also take a more severe or even fatal course, resulting in liver failure [33, 37]. In particular, a mortality of up to 75% in patients with pre-existing chronic liver disease was described [38]. In developing countries, pregnant women are considered susceptible to such a fatal outcome of HEV infection [39, 40]. In developed countries, patients are somewhat older (>45 years of age), are predominantly male with a higher frequency of underlying liver disease or alcohol abuse and a higher frequency of nonspecific symptoms; pregnant women do not show severe disease [6]. The mortality rate is somewhat higher in these areas, probably because of older age and coexistent illnesses.

Moreover, although HEV has been believed for many years to cause acute infections, but without progression to chronic infections, evidence is now emerging that HEV infections are not resolved in every case, and that in immunocompromised patients chronic infections, some with fatal outcome, also occur [41–46].

Mortality has been reported by the World Health Organization (WHO) to be 0.5–4.0% of the overall patient population, and to be up to 20% in pregnant women [34]. However, it must be mentioned that the origin of these older data has not been clearly specified, and it should be assumed that they derived from developing countries and thus from countries with insufficient health care and in which the more pathogenic HEV genotypes 1 and 2 are common.

**Epidemiology**

The spread of HEV among a population can be assessed by determination of antibodies of the IgG class against HEV. Using this method, epidemiological data have been obtained from several European countries: in Sweden, the seroprevalence of HEV has been reported to be 9.3% in the rural population, and to be somewhat but not significantly, higher in pig farmers (13.0%) [47]. Using samples derived from a serological surveillance program of the Health Protection Agency in the UK, a seroprevalence of 13.0% was found in England in 1991, and of 13.5% in 2004 [48]. Subsequently, although the investigated study population of gynecological and orthopedic hospital admissions was smaller (n = 100) than in the aforementioned report, and probably less representative for the investigated study population of gynecological and orthopedic hospital admissions was smaller (n = 100) than in the aforementioned report, and probably less representative for the general population, a comparable seroprevalence of 14% was reported from Flanders (Belgium) [49]. This is a higher seroprevalence than that found in another serosurvey undertaken among homeless people in Marseille, which yielded a seroprevalence rate of 11.6% [50]. This value is rather high compared to other regions in Southern Europe: the seroprevalence of 13.0% was found in England in 1991, and of 13.5% in 2004 [48]. Subsequently, although the investigated study population of gynecological and orthopedic hospital admissions was smaller (n = 100) than in the aforementioned report, and probably less representative for the general population, a comparable seroprevalence of 14% was reported from Flanders (Belgium) [49]. However, before assuming a north-south divide in Europe concerning the seroprevalence of HEV, it should be noted that the compatibility of all these seropreva-
In the general population in Germany was estimated to be 3.9 per 1,000 persons [55].

In Germany, information on the incidence of HEV infections (according to the Infection Protection Act) shows that the majority of notified German hepatitis E cases were acquired in Germany, and that there was no connection with travel to endemic areas (fig. 1). The few HEV cases that have so far been phylogenetically analyzed in Germany confirm the close relationship to pig isolates found in various other European countries [56]. The annual incidence of HEV infections reported in compliance with the IfSG has increased steadily over the past few years [57], while the proportion of HEV infections in men has remained constant, at about two thirds (fig. 1). In 2012, approximately half of the reported HEV infections in Germany were persons aged 40–59 years. Most blood donors are recruited from this collective. The same trend was seen in

---

**Fig. 1.** Notifications of HEV infections in Germany in compliance with the IfSG (Infection Protection Act) (Source: Robert Koch-Institut: SurvStat, www3.rki.de/SurvStat). The overall notification of HEV infections, the proportion of autochthonous acquired HEV infections, and the age and gender distribution is given.

<table>
<thead>
<tr>
<th>Year</th>
<th>Total</th>
<th>Autochthonous infections (%)</th>
<th>Gender (%)</th>
<th>Age Class (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>male</td>
<td>female</td>
</tr>
<tr>
<td>2006</td>
<td>51</td>
<td>43.1</td>
<td>64.7</td>
<td>35.3</td>
</tr>
<tr>
<td>2007</td>
<td>73</td>
<td>61.6</td>
<td>67.1</td>
<td>32.9</td>
</tr>
<tr>
<td>2008</td>
<td>104</td>
<td>67.3</td>
<td>60.6</td>
<td>39.4</td>
</tr>
<tr>
<td>2009</td>
<td>109</td>
<td>80.7</td>
<td>66.1</td>
<td>33.9</td>
</tr>
<tr>
<td>2010</td>
<td>221</td>
<td>72.9</td>
<td>62.0</td>
<td>38.0</td>
</tr>
<tr>
<td>2011</td>
<td>238</td>
<td>78.2</td>
<td>55.7</td>
<td>44.3</td>
</tr>
<tr>
<td>2012</td>
<td>386</td>
<td>*</td>
<td>63.5</td>
<td>36.5</td>
</tr>
</tbody>
</table>

* unstated
other European countries with autochthonous HEV infections, e.g. the UK [58, 59] and the Netherlands [60].

A clear correlation between the seroprevalence of HEV and age is obvious in the majority of the aforementioned reports. An increase in the seroprevalence has been noted in the older population, consistent with lifelong exposure to the virus. The reason for this observation is likely to be related to the mode of transmission of HEV genotype 3: meat or offal consumption is a major route of HEV transmission in Germany and other developed countries [57]. HEV has been detected in retail pork meat products [61–63]. The resistance to cooking in temperatures up to 60 °C [64], as well as the seasonal variation of autochthonous hepatitis E with peak in the summer [36], provides evidence that a higher consumption of meat, especially medium rare pork in the summer season (e.g. barbecues) represents a risk for HEV infections.

It might be expected that seroprevalence data obtained from blood donors in different industrialized countries should be more homogeneous due to a more homogeneous study population, but data from several European countries and Japan differ widely: they cover the considerable range of 0.4–52.2%. These data are provided in more detail in table 1, along with the number of donors included in the different studies and the methods for antibody screening and confirmation, if confirmation was performed at all. As already noted above, differences are attributed not only to the number of donors investigated, but also to the antibody tests used for the antibody screening, as well as supplemental, confirmatory assays performed. Several test strategies were applied: (1) ELISA was considered positive if a single reactive result was obtained; (2) a repeatedly reactive result was required for a positive result; (3) ELISA-reactive results were confirmed by a second ELISA; (4) confirmation was performed by Western blot analysis; (5) no confirmation of ELISA-reactive results was performed; and (6) Western blot analysis was primary used for screening. Beside differences in the tests, eating habits in the different countries may also be an explanation for the different seroprevalence values. The samples for a French study that determined a seroprevalence of 52.2% had all been collected in the Midi-Pyrénées region. A local delicacy in this region is a cured pig-liver sausage, which is usually eaten uncooked. HEV RNA was detectable in a high proportion of these sausages [65]. However, diet cannot explain the different seroprevalence found by another serosurvey that has been carried out among blood donors in the identical region but with another test [66]. Thus, there is convincing evidence that different sensitivity, as well as different specificity, of the tests used may contribute to the wide-ranging seroprevalence data. Data about the incidence of HEV in blood donors are available only for Germany (0.35% per year [67]).

### Blood Transmission

Even if large differences in the seroprevalence in several countries are existent and seroprevalence cannot be estimated exactly, there is clear evidence that a considerable proportion of blood donors were infected with HEV. Furthermore, the common finding of an age-dependent increase in seroprevalence suggests that many infections occur in middle age, and thus during the period of blood donation activity (fig. 1).

HEV RNA was detected in 13 out of 16,125 (0.08%) blood donors [28]. In another study, out of 23,500 donors, 35 (0.14%) were found per year to have detectable HEV RNA [67]. The rate of HEV RNA-positive donations was reported to be 1:7,986 in Sweden and 1:4,525 in Germany [29]. The blood-

<table>
<thead>
<tr>
<th>Country</th>
<th>n</th>
<th>Seroprevalence, %</th>
<th>Method</th>
<th>Year [reference]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Japan</td>
<td>12,600</td>
<td>3.4</td>
<td>ELISA (in-house*, Cosmic corporation**)</td>
<td>2010 [127]</td>
</tr>
<tr>
<td>Denmark</td>
<td>461</td>
<td>20.6</td>
<td>ELISA* (in-house)</td>
<td>2008 [128]</td>
</tr>
<tr>
<td>Switzerland</td>
<td>550</td>
<td>4.9</td>
<td>ELISA* (MP Biomedicals)</td>
<td>2011 [129]</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>1,275</td>
<td>0.4</td>
<td>ELISA* (Abbott, Diagnostic Biotechnology), Westernblot**</td>
<td>1993 [130]</td>
</tr>
<tr>
<td>Germany</td>
<td>336</td>
<td>5.94</td>
<td>Western blot (Mikrogen*), ELISA (MP Biomedicals**)</td>
<td>2012 [28]</td>
</tr>
<tr>
<td>Germany</td>
<td>1,019</td>
<td>6.8</td>
<td>ELISA* (Mikrogen), Western blot** (Mikrogen)</td>
<td>2013 [67]</td>
</tr>
<tr>
<td>Germany</td>
<td>116</td>
<td>15.5</td>
<td>Western blot* (Mikrogen)</td>
<td>2011 [54]</td>
</tr>
<tr>
<td>England/Wales</td>
<td>262</td>
<td>10.0</td>
<td>ELISA* (Wantai), NAT*** (in-house)</td>
<td>2011 [131]</td>
</tr>
<tr>
<td>Scotland</td>
<td>1,559</td>
<td>4.7</td>
<td>ELISA* (Wantai)</td>
<td>2013 [59]</td>
</tr>
<tr>
<td>France</td>
<td>1,998</td>
<td>3.2</td>
<td>ELISA* (Genelabs Diagnostics)</td>
<td>2007 [132]</td>
</tr>
<tr>
<td>France</td>
<td>529</td>
<td>16.6</td>
<td>ELISA* (Genelabs Diagnostics)</td>
<td>2008 [66]</td>
</tr>
<tr>
<td>France</td>
<td>512</td>
<td>52.2</td>
<td>ELISA* (Wantai)</td>
<td>2011 [65]</td>
</tr>
</tbody>
</table>

*Screening assay.
**Supplemental assay for confirmation.
***ELISA-positive samples were investigated by NAT.
borne transmission of HEV was demonstrated by the experimental infection of a Rhesus monkey with a plasma sample derived from a donor suffering from an acute HEV infection [68].

However, although presence of HEV RNA in blood donors is thus not a rare event, and HEV is obviously a blood-borne pathogen, only a few cases of transfusion-transmitted HEV infections have been documented from industrialized countries. The first was in 2004, when a case of a clinically manifested HEV infection after transfusion of 23 blood products in Japan was described. A nucleic acid amplification technique (NAT) investigation of archive samples and sequence analysis of the NAT products revealed that the HEV infection could be linked to a fresh frozen plasma: the HEV RNA detected in the donor showed complete identity for 2 distinct regions of HEV genome compared to those detected in the recipient. Although it could not be ruled out that the occurrence in both the patient and the donor was just an accidental coincidence of a HEV strain widespread in Japan, and even though the red blood cell unit obtained from the same donation as the plasma did not lead to HEV transmission, the report gave further evidence about the transfusion transmissibility of HEV [21]. 2 years later, a transfusion-transmitted HEV infection through a red blood cell unit was reported from the UK. While in the transfusion recipient the infection was asymptomatic apart from a mild jaundice and an elevation of liver enzymes, the donor became ill from an acute HEV infection, and the illness of the donor and diagnosis of HEV infection led to the investigation of the recipient [19]. In the following year, a further case of a child who suffered from transfusion-transmitted HEV infection after administration of a red blood cell unit was reported in France [20]. In both cases, from the UK and France, sequence homology in donor and recipient suggested a correlation between the transfusion and the HEV infection by genotype 3 of the recipients.

Another case of transfusion-transmitted HEV infection was reported from Japan. A retrospective investigation revealed that the donor of a platelet concentrate became infected through consumption of grilled pork 23 days before donation. Subsequently, the infection had been transmitted to the recipient by transfusion [22].

Why transfusion-transmitted HEV infections are so rarely reported remains unclear: it is possible that a frequently subclinical or asymptomatic course occurs in the affected recipients, or that treating physicians may fail to recognize transfusion-transmitted HEV in many cases. An impressive example of the latter scenario was provided by the latest case report of a transfusion-transmitted HEV infection: the symptoms of the acute HEV infection in the recipient were initially interpreted as drug-induced liver toxicity and thereafter as an autoimmune disorder, before HEV infection was considered [69]. Moreover, it can also be assumed that the quantity of infectious virus remaining in blood components, and particularly in red blood cell concentrates, is insufficient to infect the recipients in many cases. In one report, no infection of a recipient occurred until 41 days after transfusion of a red blood cell unit taken from a donor with a low-level viremia, presumably below 125 IU/ml plasma [67].

So far there have been no reports about a transmission of HEV through plasma derivatives, although a recent report referred to a contamination of approximately 10% of plasma pools with HEV RNA. However, HEV RNA concentrations were rather low (≤1,000 copies/ml) [70] in all of these contaminated plasma pools. In contrast, no HEV RNA was present in the ready-for-use coagulation factor concentrates derived from 8 different manufacturers in another investigation [71].

As it possesses no envelope, HEV should not be affected by the solvent detergent process, and heat sensitivity of HEV varies depending on the plasma stabilizers and heating conditions. Nanofiltration seems to offer an appropriate measure to remove HEV, but due to the size of HEV, filters with a pore size of approximately 20 nm are required for this purpose [72].

### Laboratory Diagnosis

In addition to clinical symptomatic diagnosis, hepatitis E infection is characterized by a number of typical biochemical markers, including bilirubinuria, elevated serum levels of bilirubin and alanine and aspartate aminotransferases (ALT, AST), and in some cases an increase in serum levels of alkaline phosphatase (ALP). However, these biomarkers are not specific to hepatitis E, and also occur in other forms of liver injury. In particular, the formerly used viral surrogate marker ALT is not always elevated in acute HEV infections [28]. Therefore, more specific and sensitive approaches are needed to diagnose HEV infection.

The laboratory diagnosis of HEV infection includes visualization of the pathogen by microscopic assays, detection of 1 of its components, e.g. protein (antigen assay) or nucleic acid (NAT), or indirect determination by detection of antibody against the virus [75]. A survey of direct and indirect approaches is summarized in figure 2.

Currently, direct cultivation of HEV in cell lines is not a routine method. Early studies reported the propagation of HEV in either primary hepatocytes or several established cell lines, but replication was inefficient. Recently, efficient cell culture systems for HEV in PLC/PRF/5, A549, PICM-19, and HepaRG cells have been established [74, 75]. Time will show if these models represent tools for diagnosis, or for studying the viral biology of HEV.

Novel techniques, such as an HEV-specific interferon-gamma (IFN-γ) ELISPOT that measure HEV-specific cell-mediated immune responses are not yet suitable for routine use [76]. This assay might provide a better measure of prior HEV exposure than seroprevalence studies. However, further studies are needed and its application is only for selected cases.

The aims of testing for HEV infection are to differentiate between acute and recent infection. An acute infection status...
...is relevant to blood safety because of the high potential of transfusion-transmitted infection, whereas the later is important for seroepidemiological studies to assess the risk of HEV infection in a population. So far, the most frequently used strategy is the testing for the presence of HEV IgG and IgM in combination with reverse transcriptase (RT) PCR on nucleic acids extracted from stool and serum/plasma in order to detect/exclude acute HEV infection.

Detection of Anti-HEV Antibodies

Diagnosis of hepatitis E is usually determined serologically by detection of the presence of IgM antibodies or rising anti-HEV IgG titers. The 4 HEV genotypes cause very similar antibody responses, suggesting a single serotype [16, 77]. In the past, serodiagnosis of hepatitis E demonstrated limitations, including viremia with a relatively small or without any antibody response in symptomatic, as well as symptom-free individuals [78, 79], a diverting IgM positivity [80] and undetectable or disappearing anti-HEV IgG antibodies [78, 81]. The HEV antigens used until now in enzyme-linked immunosorbent assays (EIAs) were produced synthetically or recombinantly via at least 2 expression systems (Escherichia coli and baculovirus, [82]), differing in the viral strain origin (Pakistani, Burmese, or Mexican) and the viral gene product (ORF2 or ORF3 [83]). Unfortunately, this resulted in a significant variation of assay sensitivities, specificities and performances [84–86]. Antigens of most HEV immunoassays were derived from genotype 1 viruses; therefore, their applicability to HEV genotype 3 infections is indeterminate [84]. Vollmer et al. [87] systematically characterized serological assays using seroconversion panels of virologically confirmed HEV genotype 3-infected individuals. The presence of anti-HEV antibodies was determined using various immunological assays: recomWell HEV IgM, recomWell HEV IgG (Mikrogen), HEV-IgM-ELISA3.0, HEV-ELISA, HEV-ELISA4.0, AssureHEV-IgM Rapid Test (MP Biomedicals), and the Anti-HEV-ELISA (IgM, IgG, Euroimmun). Assay sensitivities were evaluated by testing a series of serially diluted WHO reference reagent for hepatitis E virus antibody and 1 patient sample. Comparison of anti-hepatitis E virus antibody seroconversion was performed in 10 blood donors. Anti-HEV assays differ in their sensitivities for detecting HEV infection, with anti-HEV IgM assays being more divergent than anti-HEV IgG assays. Furthermore, the detection period of IgM antibodies significantly varies between the different assays: anti-HEV IgM antibodies are detectable over a considerably longer time period using the HEV-IgM-ELISA3.0.

Previous studies have reported that the detection of anti-HEV IgA is a convenient complementary marker for the diagnosis of HEV infection [88–90], especially regarding the enhanced specificity of a combination of both anti-HEV IgM and IgA immunoglobulins. Like IgM, IgA anti-HEV antibodies appear during acute hepatitis E. However, Herremans and coworkers [90] reported infections with HEV genotype 3 without an increase of IgA antibodies. Detection of anti-HEV IgA can be a useful supplement for diagnosis of acute HEV infection, especially in patients negative for anti-HEV IgM. In conclusion, little is known about the time course of the IgA response and the diagnostic importance in HEV infection.

Detection of HEV Antigens

As is the case for other transfusion-transmitted viruses (antigens), e.g. hepatitis B virus (HBsAg), HIV-1 (p24 antigen) or hepatitis C virus (core antigen), a suitable HEV antigen assay would be a reasonable addition to the test portfolio, and could allow the easy direct detection of the pathogen in samples such as serum or stool. Single testing of blood donors would then be easier in practice than molecular genetic screening.

The antigenic epitopes used in HEV antibody assays are primarily the capsid (ORF2) protein, and occasionally the ORF3 protein [87]. Despite the genetic variability of HEV genotypes, antibody response targets the capsid epitopes, corresponding to neutralization of the pathogen. Therefore, indirect sandwich EIA detection uses monoclonal antibodies against HEV capsid protein for HEV antigen capture and detection with another biotin-labeled anti-HEV-ORF2 antibody.
the diagnosis of HEV infection [92]. Approximately 44.6% of sera positive for anti-HEV IgM alone, 28.6% positive for both anti-HEV IgM and IgG, and 0% positive for anti-HEV IgG alone were also positive for HEV antigen using this EIA. For 42 HEV antibody-positive sera tested for HEV RNA and antigen in parallel, the concordance was 81.0% (34/42). All PCR products were found to belong to HEV genotype 4. To evaluate the temporal relationship among HEV antigen positivity and HEV RNA, anti-HEV IgG and IgM, and ALT concentrations, macaques were infected with HEV genotypes 1 and 4 and serial samples were collected. The results showed that the antigen EIA can detect the capsid proteins of both genotypes. HEV antigen was detectable prior to ALT elevation and the appearance of anti-HEV antibodies in the infected monkeys, and lasted for several weeks in all cases. HEV antigen became detectable in the serum at almost the same time as HEV RNA in feces, but persisted for 4 weeks less than HEV RNA. This assay should be valuable for the diagnosis of acute hepatitis E, particularly in the window period prior to seroconversion to anti-HEV [91].

The concordances between HEV antigen and HEV RNA, and between HEV antigen and anti-HEV IgM, were 77.1% and 72.9%, respectively, with significant correlations, while that between HEV RNA and anti-HEV IgM was 61.4% with no significant correlation. 11 of 25 samples negative for anti-HEV IgM were positive for HEV antigen. The ALT, AST, ALP, total iron-binding capacity (TBA), gamma-glutamyl transferase (GGT), total bilirubin, and direct bilirubin levels were significantly higher in the HEV antigen-positive group than in the HEV antigen-negative group. All of the HEV isolates cloned belonged to genotype 4. HEV antigen was highly correlated with HEV RNA and elevated ALT, AST, ALP, TBA, and GGT levels. Testing for HEV antigen in combination with anti-HEV IgM is useful for the diagnosis of HEV infection [92].

In an Indian study, the use of hepatitis E virus antigen detection as an early diagnostic marker in an outbreak, in comparison to anti-HEV IgM and RT-PCR analyses, was determined [92]. The positivity for anti-HEV IgM, HEV antigen, and RT-PCR was 91.6%, 69.4%, and 47.2%, respectively. RT-PCR and HEV antigen detection gave the highest positive results (100%) in the first 3 days of illness. Positive HEV PCR declined to 54% by days 4–7, whereas HEV antigen and IgM detection were 88% and 100%, respectively. HEV antigen was found to be an early diagnostic marker of acute infection, and was detected in 3 additional cases in the early phase (1–3 days), without detectable anti-HEV IgM antibodies. These 3 samples were also positive for HEV RNA. After day 7, anti-HEV IgM was the main diagnostic indicator of infection [93].

Detection of HEV RNA

Today, HEV can be reliably detected using NATs in the active phase of infection in serum, plasma or fecal samples. HEV RNA screening is primarily performed in blood samples (plasma). Several in-house NAT methods have been described using nested RT-PCR [56, 93–95], real-time RT-PCR [97–102] or loop-mediated isothermal amplification [103]. For the later technique, sensitivity higher than that for RT-PCR was shown but experience with this assay is limited to 1 study [103].

The main focus is on real-time detection methods using fluorescent probes. For diagnosis, the majority of HEV RT-PCR assays have used conserved HEV genomic regions as the target for amplification. Considering the wide genetic heterogeneity of HEV isolates, it is critical to design primer and probes that guarantee the development of highly sensitive and broadly reactive assays [17]. One of the most widely used of these real-time RT-PCRs is that developed by Jothikumar and colleagues [97]. Garson et al. [104] recommended an improvement using a minor-groove-binder (MGB)-modified probe. They demonstrated that the MGB-modified probe detected HEV RNA in plasma samples from 6 patients with serologically confirmed hepatitis E in whom the unmodified probe had failed to detect HEV RNA. The sequence analysis of the RT-PCR target ORF3 segment revealed an identical C→T single nucleotide mutation in the probe-binding region in each case.

Therefore, a defined panel of HEV genotypes and isolates is necessary to test the HEV NAT assays. In a collaborative study the performance of HEV NAT assays was evaluated using a panel of HEV-containing plasma samples of genotypes 3a, 3b, 3f, and 4c [105]. The results of the study demonstrated a 100- to 1,000-fold difference in sensitivity between the majority of assays, independent of the virus strain. The broad variability in assay sensitivity between different laboratories illustrated the need for a well-characterized reference standard for use in standardizing NAT assays to detect and quantify HEV RNA. This study was instrumental in establishing a WHO standard for HEV RNA for NAT-based assays. This was endorsed by the WHO Expert Committee on Biological Standardization (ECBS) in 2009 (WHO/BS/09,2126) and, following the initial study, 2 virus strains were selected for further development as a candidate international standard for the WHO and a candidate Japanese National Standard in collaboration with the National Institute of Infectious Diseases (NIID) in Japan. The viral strains being developed as standards are genotype 3a and 3b HEV strains, which were equally well detected in the initial study and belong to the widely distributed genotype 3. Results from the collaborative study to evaluate candidate standards for HEV RNA for use in NAT-based assays were published in October 2011 [106].

In 2012, the first WHO international standard for HEV RNA was established as a genotype 3a strain with a unitage of 250,000 IU/ml [106]. First studies using this standard have provided data to compare HEV NAT assays [28, 29].

Currently, there are several commercially available HEV RT-PCR assays that are used for HEV screening studies. Vollmer et al. [28] have demonstrated high sensitivity of real-time PCR assay and applicability for routine blood donor mini-
pool screening. Compared to published in-house HEV RT-PCRs, the RealStar HEV RT-PCR Kit (Altona Diagnostics, Hamburg, Germany) showed a 10-fold higher analytical sensitivity. Using a nucleic acid extraction from high-volume plasma (4.8 ml, chemagical viral DNA/RNA reagent kit, PerkinElmer Chemagen Technologie GmbH, Baesweiler, Germany), this real-time assay revealed a 95% lower limit of detection (LOD) of 4.66 IU/ml. Novel assays, e.g. HepatitisE@ceeram ToolsTM, health kit (Ceeram, La Chapelle-Sur-Erdre, France), ampliTaqCube HEV RT-PCR (Mikrogen, Neuried, Germany) show a lower analytical sensitivity (data not shown [107]).

To estimate the risk of HEV transmission through transfusion, the incidence of HEV infections in the blood donor population has to be analyzed. The NAT screening study recently observed a widespread distribution of HEV in plasma fractionation pools and plasma donations from Sweden and Germany, whereas plasma fractionation pools from the Middle East, as well as 51,075 individual donations from the USA, showed no contamination with HEV RNA [29, 70]. Approximately 10% of plasma pools were positive for HEV RNA (sources: North America, Europe, Southeast Asia, [70]) and the rate of individual HEV RNA-positive donors varies from 1.7986 (0.012%, Sweden), 1.7040 (0.014%, UK) [109], and 1.4525 (0.022%, Germany) [29]. Other studies from Asia revealed hepatitis E viremia among blood donors of at least 0.3% (Japan, [110], donors with elevated ALT: 1.1% [27]). However, in Germany, a considerably higher rate of 1:1,240 HEV RNA-positive donors (0.08%) has also been observed [28]. Possible explanations are, on the one hand, effects of the particular donor population, especially within the context of the zoonotic potential and transmission of HEV. On the other hand, this might be due to the fact that this screening method showed a 95% LOD of 4.66 IU/ml, which is increased by factor 50 compared to the assay used by Baylis and coworkers (250 IU/ml [29]). Observed viral loads in this study varied from 18.6 to 2.6 x 10^4 IU/ml, showing values in similar ranges recently reported for German or Swedish donations (1.6 x 10^5 to 4.8 x 10^5 IU/ml) [29]) or Japanese blood donors (79 to 3.1 x 10^2 copies/ml) [27].

HEV Prevention and Control of Infection

To prevent HEV infection, the provision of safe drinking water, proper disposal of human feces, and personal hygiene are required. During outbreaks, chlorination or boiling of water is useful. In areas with zoonotic transmission of HEV, proper cooking of meat, especially from pigs, is recommended to prevent food-borne transmission.

As already implemented for the hepatitis A virus, the development of active immunization should be the goal. No HEV vaccine is currently licensed for marketing. The development of a vaccine has so far been hampered because HEV has been difficult to replicate in cell culture [111]. Recent successes in cell culture of HEV have been recorded [112], possibly leading to vaccine development and a better understanding of the virus biology. At present, no vaccines on the basis of inactivated viruses or nonpathogenic isolates are available [112]. However, other approaches, such as DNA-based vaccines, or recombinant proteins, able to induce both cellular and antibody response are under evaluation [111, 114]. Several HEV immunization studies are based mainly on recombinant proteins. The ORF2 protein (capsid) has been considered the best candidate for HEV vaccine because it contains a neutralization epitope [115] and is cross-reactive with all mammalian HEV [116].

Although HEV vaccine trials, including trials conducted in populations in southern Asia, have shown candidate vaccines to be effective and well-tolerated, these vaccines have not yet been produced or made available to susceptible populations [117, 118]. However, prospects for control of HEV infection are encouraged by recent efforts in vaccine development [119, 120]. A new recombinant HEV vaccine has been developed by Chinese scientists that protects recipients from both infection (> 70% efficacy) and disease (>90% efficacy) for up to 3 years [120]. This vaccine will be the first that is commercially available and has been licensed for production and sale by the State Food and Drug Administration of China [121]. However, no comparative data on the safety and immunogenicity of these vaccines are available and the focus of studies has been on clinical disease and not HEV infection rates. It is thus unclear whether these vaccines can reduce HEV transmission.

Additionally, whether HEV vaccines should be used for the general population in high endemic areas or only for high-risk groups (such as patients with chronic liver disease, immunosuppressed persons, pregnant women or children) has to be discussed.

Treatment for acute or chronic HEV infection is generally supportive. Most patients need no specific treatment because the illness is self-limiting. Some patients with severe acute HEV infection have responded to ribavirin therapy, but this treatment is contraindicated in pregnant women. IFN-α-2a/2b and ribavirin therapy, separately or in combination, has been used for patients with chronic infection [122–125].

Conclusion

The risk of transfusion-transmitted HEV infection is still under discussion. Risk assessment is difficult to determine due to the large proportion of asymptomatic and undiagnosed HEV infections, the unknown efficiency of pathogen reduction techniques, and the lack of data from long-term systematic routine NAT screening. Severe or fatal HEV infections with a high morbidity and mortality have been observed in pregnant women, immunosuppressed individuals, and patients with pre-existing liver disease. Chronic disease progression, particularly observed in solid organ transplant reci-
ents, raise concerns because treatment is still evolving and vaccines are not yet available. Basically information on HEV virology and epidemiology is required combined with the development of seroconversion and/or genotype-specific panels and standards to allow validation of NAT and serological assays. In the short-term view, studies in blood donors using validated, standardized NAT assays are feasible to evaluate the potential exposure risk to transfusion recipients. For this purpose, the first WHO International Standard for HEV RNA [105, 107] and a panel of virologically confirmed clinical samples [87] would help to characterize NAT assays. The NAT-based screening of blood donors in large-scale studies will provide data on HEV incidence, and will increase the safety of blood components by exclusion of viremic (NAT-positive) donors. Recipients of blood transfusion should be analyzed using serological and NAT assays to assess whether transfusion-transmitted HEV can be confirmed in available repository samples or in prospective studies. The risk of HEV transmission by plasma products is currently estimated to be low since steps have been introduced for most of the products (except for solvent/detergent-treated plasma) that are considered to be at least partly effective in deactivating or removing HEV [30]. The data available on non-enveloped model viruses, such as feline calicivirus, cannot clearly be transferred to HEV. In addition, the effectiveness of the deactivation methods developed for plasma and cellular blood products is currently unknown. Therefore, it has to be considered whether HEV NAT screening should be adopted in the routine testing procedure for blood donations. Currently, HEV NAT screening is the only precautionary measure to prevent transfusion-transmitted HEV infection, as neither antibody detection nor surrogate markers for HEV infection, especially ALT measurement, correlate with the acute HEV infection and detection of HEV RNA in plasma, respectively. Only HEV antigen tests may possibly offer a feasible screening method in the future. This is very important for cellular blood components that cannot be treated with pathogen inactivation, or retesting after quarantine storage. Actually, the proposal is to amend the European pharmacopoeia monograph 1646 – human plasma (pooled and treated for virus inactivation) [126]. The amendment would see the introduction of HEV NAT with a possible implementation in January 2015. The authors conclude that recent studies provide clear evidence for a transfusion-associated risk of HEV. Therefore, HEV NAT screening for blood products is a meaningful consideration for the near future.

Recent successful clinical testing of HEV vaccines bodes well for the future, perhaps establishing a vaccination program for children and/or blood donors combining hepatitis A, B and E virus.

Acknowledgements

The authors thank Tanja Vollmer and Holger Hennig for critical reading of this manuscript, as well as Sarah Kirkby for her linguistic advice.

Disclosure Statement

The authors declare that they have no conflict of interest.

References


Infections Transfusion-Associated Risk of HEV Infections


